Echo IQ (ASX:EIQ) struck a research collaboration agreement with Mayo Clinic to evaluate the ability of Echo's proprietary artificial intelligence platform to estimate cardiac risk in cancer patients, according to a Friday filing with the Australian bourse.
The research will assess the platform's ability to generate predictive risk scores for heart failure based on echocardiogram data for oncology patients.
The study will also aims to assess the applicability of the AI platform in a "large and clinically important patient population beyond its current cardiovascular applications," the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments